Akums launches generic formulation to treat migraine
时间:2024-06-26 08:44:01 阅读(143)
Akums Drugs & Pharmaceuticals Ltd., a contract manufacturing pharmaceutical company, on Friday announced that it has launched the Lasmiditan tablet which is prescribed to treat migraine. This medication has received approvals from the Drug Controller General of India (DCGI) and the United States Food and Drug Administration (USFDA).
It is the generic formulation of Eli Lilly’s REYVOW which is indicated for treatment of acute migraine.
In a 2019 report, it was revealed that headache disorders, including both migraines and tension-type headaches, have emerged as the most prevalent neurological conditions in India, affecting an astonishing 488 million individuals.
The International Headache Society (IHS) outlines criteria for diagnosing migraine, including specific characteristics and associated symptoms observed in at least five attacks. Two main subtypes, migraine without aura and migraine with aura, present distinct features, with the latter involving focal neurological symptoms preceding or accompanying the headache.
“Migraine poses a significant global impact. According to a 2019 report, headache disorders, encompassing migraine and tension-type headaches, emerged as the most widespread neurological conditions in India, impacting a staggering 488 million individuals. Despite this substantial prevalence and the resulting disability, migraine awareness among patients remains inadequate. Compounded by frequent misdiagnosis as other headache disorders, these factors contribute to an increased burden associated with migraine. In light of this, Akums aims to provide a solution for managing this condition with the introduction of the Lasmiditan tablet,” Sanjeev Jain, Joint Managing Director, Akums Drugs & Pharmaceuticals Ltd., said.
猜你喜欢
- PSLV-C56 Launch- ISRO launches 7 Singapore satellites in a picture-perfect lift off! See Photos
- Dhanlaxmi Bank shares recover from plunge led by director exit
- Markets Wrap – Thu, 9 Mar ‘23- Nifty, Sensex plunge, rupee rises; Asia, US markets, Gold, Crude updates
- Markets trade higher in early trade amid firm global equities
- Markets tomorrow- Nifty, Sensex end over 1% up; Markets remain positive, Bank, Auto, defence sectors in focus
- Does the global recession impact India’s stock market-
- Mcap of five of top-10 most valued firms jumps Rs 86,234
- Mcap of BSE-listed firms at all-time high of over Rs 280
- Prudent Corporate Advisory IPO share allotment- Check status online, grey market premium; listing on May 23